Characterizing the Impact of Induction Therapy on BK Polyoma Viral Reactivation: A Single-Center Analysis
Transplantation Proceedings · 2026
DOI: 10.1016/j.transproceed.2026.01.023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplantation Proceedings, 2026. Verfasst von Shahed Ammar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa; University of Texas Medical Branch, Galveston, Texa…. Hauptthemen laut MEDLINE: BK Virus, Immunosuppressive Agents, Kidney Transplantation, Virus Activation. Die Arbeit nennt 17 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: BKPyV following kidney transplantation is well recognized to cause premature graft failure and ureteral complications. Cumulative immunosuppression, including induction therapy, has a sustained impact on immune responses to opportunistic infection. We hypothesized that induction with cell-depleting agents affects the 1-year risk of BKPyV reactivation. METHODS: Of 456 adult patients who underwent kidney transplants between January 2018 and February 2023 with at least 12 months of follow-up were screened for BK virus by blood PCR at 1.5, 3,6,9,12 months. RESULTS: Among the 456 patients, 101 (22.1%) developed BKPyV viremia. The incidence of BKPyV positivity was highest with basiliximab (32%) compared to alemtuzumab (21%) and thymoglobulin (18%) (p = .032). Compared to basiliximab, receiving alemtuzumab (OR: 0.571, 95% CI: 0.329-0.991, p = .042) or thymoglobulin (OR: 0.462, 95% CI: 0.256-0.834, p = .010) was associated with a significantly lower risk of BKPyV. Higher KDPI was also significantly associated with an increased risk of BKPyV infection (OR: 1.120, 95% CI: 1.013-1.238, p = .026). Multivariable analysis showed a persistently significant lower risk of BKPyV infection with thymoglobulin (OR: 0.4, 95% CI: 0.21-0.75, p = .004) and alemtuzumab (OR: 0.5, 95% CI: 0.28-0.89, p = .019) compared to basiliximab. Also, higher KDPI was independently associated with BKPyV viremia (OR: 1.13, 95% CI: 1.01-1.25, p = .031). CONCLUSION: Induction therapy and higher KDPI were significant risk factors for BKPyV reactivation. Induction with cell-depleting agents lowered the risk of BKPyV, perhaps due to the subsequent use of lower maintenance immunosuppression and reduced need for acute rejection treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa; University of Texas Medical Branch, Galveston, Texas. Electronic address: ammarshahed@gmail.com.
- Institute for Clinical and Translational Science, Carver College of Medicine, University of Iowa, Iowa City, Iowa.
- Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, Iowa; UH Cleveland Medical Center, Cleveland, Ohio.
- Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa.
Zitieren
APA
Ammar, S., Eyck, P. T., Axelrod, D., Tan, C. S., & Kuppachi, S. (2026). Characterizing the Impact of Induction Therapy on BK Polyoma Viral Reactivation: A Single-Center Analysis. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2026.01.023
Vancouver
Ammar S, Eyck PT, Axelrod D, Tan CS, Kuppachi S. Characterizing the Impact of Induction Therapy on BK Polyoma Viral Reactivation: A Single-Center Analysis. Transplantation Proceedings. 2026. doi:10.1016/j.transproceed.2026.01.023
BibTeX
@article{Ammar2026,
author = {Ammar, Shahed and Eyck, Patrick Ten and Axelrod, David and Tan, Chen S and Kuppachi, Sarat},
title = {Characterizing the Impact of Induction Therapy on BK Polyoma Viral Reactivation: A Single-Center Analysis},
journal = {Transplantation Proceedings},
year = {2026},
doi = {10.1016/j.transproceed.2026.01.023}
}
EUVIMED